Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Lung Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin

Benjamin Schneider 1 Arnaud Boyer 2, 3 Joseph Ciccolini 3 Kenneth Wang 4 Martin E Fernandez-Zapico 4 Jonathan Mochel 1 Sébastien Benzekry 5, 6
1 ISU - Iowa State University
2 APHM - Assistance Publique - Hôpitaux de Marseille
3 SMARTc - Simulation and Modeling of Adaptive Response for Therapeutics in Cancer
CRCM - Centre de Recherche en Cancérologie de Marseille
4 Mayo Clinic [Rochester]
5 IMB - Institut de Mathématiques de Bordeaux
6 MONC - Modélisation Mathématique pour l'Oncologie
IMB - Institut de Mathématiques de Bordeaux, Inria Bordeaux - Sud-Ouest, Institut Bergonié - CRLCC Bordeaux
Abstract : Situation: Bevacizumab is an anti-angiogenic drug commonly administered contaminantly with chemotherapeutic drugs for advanced non- squamous non-small cell lung cancer (NSCLC). Bevacizumab administration transiently enhances chemotherapeutic drug delivery, resulting in increased efficacy of chemotherapeutic drugs. Objective: This analysis attempts to characterize tumor growth dynamics as measured by uorescence in response to concurrent vs. sequential administration of pemetrexed-cisplatin and bevacizumab in NSCLC tumor carrying mice. Methods: Experiment: Data comes from previous experiment where 77 mice were randomized into 5 treatment groups: i) control (saline, N=15), ii) beva then pemetrexed-cisplatan after 3 days iii) beva then pemetrexed-cisplatan after 8 days iv) concomitant beva + pemetrexed-cisplatan v) pemetrexed cisplatin alone Statistical Analysis: Tumor size was evaluated by uorescence and the resulting data were analyzed using the stochastic approximation expectation maximization algorithm implemented in Monolix 2018 R1. Standard model diagnostics were completed using various R packages as well as other components of the Monolix Suite.
Document type :
Poster communications
Complete list of metadatas
https://hal.inria.fr/hal-01968942
Contributor : Sebastien Benzekry <>
Submitted on : Thursday, January 3, 2019 - 3:01:34 PM
Last modification on : Thursday, May 9, 2019 - 1:40:17 PM
Long-term archiving on : Thursday, April 4, 2019 - 3:23:30 PM

File

2018_page_Schneider_bevalung.p...
Files produced by the author(s)

Identifiers

  • HAL Id : hal-01968942, version 1

Collections

BERGONIE | PAOLI_CALMETTES | TDS-MACS | FNCLCC | INRIA | INRIA-BORDEAUX | UNIV-AMU | IMB | CRCM

Citation

Benjamin Schneider, Arnaud Boyer, Joseph Ciccolini, Kenneth Wang, Martin E Fernandez-Zapico, et al.. Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Lung Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin. Population Approach Group in Europe (PAGE) Meeting 2018, May 2018, Montreux, Switzerland. 2018. ⟨hal-01968942⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

155

Files downloads

211

Contact


archive-ouverte@inria.fr